Related Experiment Video

Updated: Jul 19, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy

Dogan Erdogan1, Hakan Gullu, Mustafa Caliskan

  • 1Cardiology Department, Konya Teaching and Medical Research Center, Baskent University, Konya, Turkey. aydoganer@yahoo.com

Heart (British Cardiac Society)
|October 27, 2006
PubMed

Insights

Nebivolol treatment significantly improved coronary flow reserve (CFR) in patients with idiopathic dilated cardiomyopathy (IDC) after one month. This beta-blocker enhanced myocardial blood flow, offering a potential therapeutic benefit for IDC patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Imaging

Background:

  • Impaired coronary flow reserve (CFR) is a key predictor of poor outcomes in idiopathic dilated cardiomyopathy (IDC).
  • Nebivolol is known to reduce mortality and morbidity in heart failure patients, including those with IDC.

Purpose of the Study:

  • To evaluate the impact of nebivolol on CFR in patients diagnosed with IDC.
  • To assess changes in coronary blood flow dynamics following nebivolol administration.

Main Methods:

  • Transthoracic Doppler echocardiography was used to measure coronary flow reserve in 21 stable IDC patients before and after one month of daily nebivolol.
  • A control group of age- and sex-matched healthy individuals was included for comparison.
  • Resting and hyperemic coronary flows were assessed, with no subjects having systemic diseases.

Main Results:

  • Nebivolol significantly reduced heart rate and blood pressure, and decreased end-systolic diameter.
  • Coronary velocities at rest decreased, while post-dipyridamole hyperemic velocities increased significantly.
  • Coronary flow reserve (CFR) showed a significant increase from 2.02 to 2.61 (p<0.001), with 80.9% of patients experiencing improvement.

Conclusions:

  • One month of nebivolol treatment markedly enhances coronary flow reserve in patients with idiopathic dilated cardiomyopathy.
  • Nebivolol demonstrates potential as a therapeutic agent to improve myocardial perfusion in IDC.
Abstract

More Related Videos

Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice05:07

Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice

Published on: August 25, 2023

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...